These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 24097870)

  • 1. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma.
    Behrens C; Solis LM; Lin H; Yuan P; Tang X; Kadara H; Riquelme E; Galindo H; Moran CA; Kalhor N; Swisher SG; Simon GR; Stewart DJ; Lee JJ; Wistuba II
    Clin Cancer Res; 2013 Dec; 19(23):6556-65. PubMed ID: 24097870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival.
    He LR; Ma NF; Chen JW; Li BK; Guan XY; Liu MZ; Xie D
    Oncotarget; 2015 Oct; 6(31):31181-90. PubMed ID: 26360781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer.
    Inoue Y; Yoshimura K; Kurabe N; Kahyo T; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
    Oncotarget; 2017 Jan; 8(5):8738-8751. PubMed ID: 28060732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
    Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
    Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological significance and prognostic role of EZH2 expression in non-small cell lung cancer.
    Kim NY; Pyo JS
    Pathol Res Pract; 2017 Jul; 213(7):778-782. PubMed ID: 28554757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Value of EZH2 in Non-Small-Cell Lung Cancers: A Meta-Analysis and Bioinformatics Analysis.
    Fan K; Zhang CL; Qi YF; Dai X; Birling Y; Tan ZF; Cao F
    Biomed Res Int; 2020; 2020():2380124. PubMed ID: 33299862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of HAb18G/CD147 and its localization correlate with the progression and poor prognosis of non-small cell lung cancer.
    Xu XY; Lin N; Li YM; Zhi C; Shen H
    Pathol Res Pract; 2013 Jun; 209(6):345-52. PubMed ID: 23602236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of SIRT1 and cortactin is associated with progression of non-small cell lung cancer.
    Noh SJ; Baek HA; Park HS; Jang KY; Moon WS; Kang MJ; Lee DG; Kim MH; Lee JH; Chung MJ
    Pathol Res Pract; 2013 Jun; 209(6):365-70. PubMed ID: 23702379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.
    Huqun ; Ishikawa R; Zhang J; Miyazawa H; Goto Y; Shimizu Y; Hagiwara K; Koyama N
    Cancer; 2012 Mar; 118(6):1599-606. PubMed ID: 21837672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
    Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
    Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of p63, TTF-1 and Maspin in Non-Small Cell Lung Carcinoma and Their Effect on the Prognosis and Differential Diagnosis.
    Yaman B; Nart D; Ekren PK; Çok G; Veral A
    Turk Patoloji Derg; 2015; 31(3):163-74. PubMed ID: 26456962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinicopathological significance of Lgr5 expression in lung adenocarcinoma.
    Ryuge S; Sato Y; Jiang SX; Wang G; Kobayashi M; Nagashio R; Katono K; Iyoda A; Satoh Y; Masuda N
    Lung Cancer; 2013 Oct; 82(1):143-8. PubMed ID: 23915911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer.
    Cao W; Ribeiro Rde O; Liu D; Saintigny P; Xia R; Xue Y; Lin R; Mao L; Ren H
    PLoS One; 2012; 7(12):e52984. PubMed ID: 23300840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine-protein phosphatase non-receptor type 12 expression is a good prognostic factor in resectable non-small cell lung cancer.
    Cao X; Chen YZ; Luo RZ; Zhang L; Zhang SL; Zeng J; Jiang YC; Han YJ; Wen ZS
    Oncotarget; 2015 May; 6(13):11704-13. PubMed ID: 25868976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis, and poor progression of gallbladder adenocarcinoma.
    Liu DC; Yang ZL
    Pathol Res Pract; 2011 Aug; 207(8):472-8. PubMed ID: 21719208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study.
    Tan D; Li Q; Deeb G; Ramnath N; Slocum HK; Brooks J; Cheney R; Wiseman S; Anderson T; Loewen G
    Hum Pathol; 2003 Jun; 34(6):597-604. PubMed ID: 12827614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer.
    Geng J; Li X; Zhou Z; Wu CL; Dai M; Bai X
    Cancer Lett; 2015 Apr; 359(2):275-87. PubMed ID: 25633838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer.
    Leinonen T; Pirinen R; Böhm J; Johansson R; Kosma VM
    Histol Histopathol; 2008 Jun; 23(6):693-700. PubMed ID: 18366007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of thyroid transcription factor-1 in primary, resected, non-small cell lung carcinoma.
    Puglisi F; Barbone F; Damante G; Bruckbauer M; Di Lauro V; Beltrami CA; Di Loreto C
    Mod Pathol; 1999 Mar; 12(3):318-24. PubMed ID: 10102618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
    Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
    Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.